Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc.
October 05 2021 - 12:56PM
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the
“Company”), a biotech/agtech R&D company engaged in the
development and commercialization of therapeutic, medicinal and
nutritional product candidates originally derived from proprietary
algal cultures, today issues a notice to its shareholders
concerning the annual shareholder meeting.
Pursuant to the Notice previously provided for
the Annual Meeting of Shareholders of Zivo Bioscience, Inc.,
("Zivo" or the "Company") to be held on Tuesday,
October 12, 2021, at 9:00 a.m. EST., the weblink for
virtual attendance is provided below.
Weblink:
https://agm.issuerdirect.com/zivo
Control ID for shareholder: For
Shareholder Control IDs, Shareholders must refer to their proxy
card received for their Control ID.
Control ID for other
participants: 000000000 (* nine zeros)
(Note: for public health concerns regarding the
coronavirus (COVID-19), the Annual Meeting will be held in a
virtual format as well as in-person at 3600 Centerpoint Parkway,
Pontiac, MI 48341.)
The Proxy Statement as filed is available
at:
-
https://ir.zivobioscience.com/all-sec-filings/content/0001654954-21-010024/zivo_def14a.htm?TB_iframe=true&height=auto&width=auto&preload=false
- as amended
https://ir.zivobioscience.com/all-sec-filings/content/0001654954-21-010296/zivo_defa14a.htm?TB_iframe=true&height=auto&width=auto&preload=false
About Zivo Bioscience, Inc.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a
Michigan-based biotech/agtech company engaged in the investigation
of the health and nutritional benefits of bioactive compounds
derived from its proprietary algal cultures, and the development of
natural bioactive compounds for use as dietary supplements and food
ingredients, as well as biologically derived and synthetic
candidates for medicinal and pharmaceutical applications in humans
and animals, specifically focused on the general benefits of
autoimmune and inflammatory response modulation. Visit
zivobioscience.com to learn more.
Forward Looking Statements
Except for any historical information, the
matters discussed herein contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Although ZIVO
believes that we have a reasonable basis for each forward-looking
statement, we caution you that these statements are based on a
combination of facts and factors currently known by us and our
expectations of the future, about which we cannot be certain. Our
actual future results may be materially different from what we
expect due to factors largely outside our control, including risks
that our strategic partnerships may not facilitate the
commercialization or market acceptance of our products; risks that
our products may not be ready for commercialization in a timely
manner or at all; risks that our products will not perform as
expected based on results of our pre-clinical and clinical trials;
our ability to raise additional funds; uncertainties inherent in
the development process of our products; changes in regulatory
requirements or decisions of regulatory authorities; the size and
growth potential of the markets for our products; the results of
clinical trials, our ability to protect our intellectual property
rights and other risks, uncertainties and assumptions, including
those described under the heading “Risk Factors” in our filings
with the Securities and Exchange Commission. These forward–looking
statements speak only as of the date hereof and ZIVO undertakes no
obligation to revise or update any forward–looking statements for
any reason, even if new information becomes available in the
future.
Contacts:
Investor RelationsCORE
IR516-222-2560Investor@zivobioscience.com
MediaCORE IRJules
Abraham917-885-7378julesa@coreir.com
Source: Zivo Bioscience, Inc.
Zivo Bioscience (NASDAQ:ZIVOW)
Historical Stock Chart
From Apr 2024 to May 2024
Zivo Bioscience (NASDAQ:ZIVOW)
Historical Stock Chart
From May 2023 to May 2024